SAFETY DATA SHEET

Tafluprost Formulation

SECTION 1. IDENTIFICATION

Product name : Tafluprost Formulation
Other means of identification : No data available

Manufacturer or supplier’s details
Company name of supplier : Merck & Co., Inc
Address : 2000 Galloping Hill Road
Kenilworth - New Jersey - U.S.A. 07033
Telephone : 908-740-4000
Emergency telephone : 1-908-423-6000
E-mail address : EHSDATASTEWARD@merck.com

Recommended use of the chemical and restrictions on use
Recommended use : Pharmaceutical
Restrictions on use : Not applicable

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the Hazardous Products Regulations
Not a hazardous substance or mixture.

GHS label elements
Not a hazardous substance or mixture.

Other hazards
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>Common Name/Synonym</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycerine</td>
<td>1,2,3-Propanetriol</td>
<td>56-81-5</td>
<td>&gt;= 1 - &lt; 5 *</td>
</tr>
<tr>
<td>Tafluprost</td>
<td>No data available</td>
<td>209860-87-7</td>
<td>&gt;= 0 - &lt; 0.1 *</td>
</tr>
</tbody>
</table>

* Actual concentration or concentration range is withheld as a trade secret

SECTION 4. FIRST AID MEASURES

If inhaled : If inhaled, remove to fresh air.
Get medical attention if symptoms occur.

In case of skin contact : Wash with water and soap as a precaution.
Get medical attention if symptoms occur.

In case of eye contact : Flush eyes with water as a precaution.
Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention if symptoms occur.
Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and delayed:
None known.

Protection of first-aiders:
No special precautions are necessary for first aid responders.

Notes to physician:
Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media:
- Water spray
- Alcohol-resistant foam
- Carbon dioxide (CO2)
- Dry chemical

Unsuitable extinguishing media:
None known.

Specific hazards during firefighting:
Exposure to combustion products may be a hazard to health.

Hazardous combustion products:
Carbon oxides

Specific extinguishing methods:
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

Special protective equipment for fire-fighters:
Wear self-contained breathing apparatus for firefighting if necessary. Use personal protective equipment.

SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures:
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions:
Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g., by containment or oil barriers). Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up:
Soak up with inert absorbent material. For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.
SAFETY DATA SHEET

Tafluprost Formulation

Version: 1.10  Revision Date: 04/09/2021  SDS Number: 558015-00011  Date of last issue: 10/10/2020
Date of first issue: 03/15/2016

Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

Technical measures: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation: Use only with adequate ventilation.
Advice on safe handling: Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Take care to prevent spills, waste and minimize release to the environment.
Conditions for safe storage: Keep in properly labeled containers. Store in accordance with the particular national regulations.
Materials to avoid: Do not store with the following product types: Strong oxidizing agents.

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glycerine</td>
<td>56-81-5</td>
<td>TWA (Mist)</td>
<td>10 mg/m³</td>
<td>CA AB OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Mist)</td>
<td>10 mg/m³</td>
<td>CA BC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Respirable mist)</td>
<td>3 mg/m³</td>
<td>CA BC OEL</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWAEV (Mist)</td>
<td>10 mg/m³</td>
<td>CA QC OEL</td>
</tr>
<tr>
<td>Tafluprost</td>
<td>209860-87-7</td>
<td>TWA</td>
<td>0.002 µg/m³ (OEB 5)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Wipe limit 0.02 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

Further information: Skin, Eye

Engineering measures: Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. No open handling permitted. Totally enclosed processes and materials transport systems are required. Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

Personal protective equipment

Respiratory protection: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type: Organic vapor Type
Hand protection: Chemical-resistant gloves
Remarks: Consider double gloving.
Eye protection: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Hygiene measures: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance: Aqueous solution
Color: clear
Odor: No data available
Odor Threshold: No data available
pH: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flash point: No data available
Evaporation rate: No data available
Flammability (solid, gas): Not applicable
Flammability (liquids): No data available
Upper explosion limit / Upper: No data available
SAFETY DATA SHEET

Tafluprost Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.10</td>
<td>04/09/2021</td>
<td>558015-00011</td>
<td>10/10/2020</td>
<td>03/15/2016</td>
</tr>
</tbody>
</table>

flammability limit

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity

Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure

Inhalation

Skin contact

Ingestion

Eye contact
Acute toxicity
Not classified based on available information.

Components:

Glycerine:
Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Acute dermal toxicity : LD50 (Guinea pig): > 5,000 mg/kg

Tafluprost:
Acute oral toxicity : LD50 (Rat): 665 mg/kg
LD50 (Rat): > 100 mg/kg
Remarks: No mortality observed at this dose.

Acute toxicity (other routes of administration) : (Dog): 3 mg/kg
Application Route: Intravenous
Target Organs: Cardio-vascular system

Skin corrosion/irritation
Not classified based on available information.

Components:

Glycerine:
Species : Rabbit
Result : No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Glycerine:
Species : Rabbit
Result : No eye irritation

Tafluprost:
Species : Monkey
Result : No eye irritation

Respiratory or skin sensitization

Skin sensitization
Not classified based on available information.

Respiratory sensitization
Not classified based on available information.
Components:

Tafluprost:
Test Type: Maximization Test
Routes of exposure: Dermal
Species: Guinea pig
Result: Not a skin sensitizer.

Germ cell mutagenicity
Not classified based on available information.

Components:

Glycerine:
Genotoxicity in vitro: Test Type: In vitro mammalian cell gene mutation test
Result: negative

Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vitro: Test Type: Chromosome aberration test in vitro
Result: negative

Genotoxicity in vitro: Test Type: DNA damage and repair, unscheduled DNA synthesis in mammalian cells (in vitro)
Result: negative

Tafluprost:
Genotoxicity in vitro: Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vitro: Test Type: Chromosome aberration test in vitro
Result: negative

Genotoxicity in vivo: Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Result: negative

Carcinogenicity
Not classified based on available information.

Components:

Glycerine:
Species: Rat
Application Route: Ingestion
Exposure time: 2 Years
Result: negative

Tafluprost:
Species: Rat
Tafluprost Formulation

Application Route: Subcutaneous
Exposure time: 24 Months
Result: negative

Species: Mouse
Application Route: Subcutaneous
Exposure time: 18 Months
Result: negative

Reproductive toxicity
Not classified based on available information.

Components:

Glycerine:
Effects on fertility: Test Type: Two-generation reproduction toxicity study
Species: Rat
Application Route: Ingestion
Result: negative

Effects on fetal development: Test Type: Embryo-fetal development
Species: Rat
Application Route: Ingestion
Result: negative

Tafluprost:
Effects on fertility: Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Intravenous injection
Fertility: NOAEL: 100 µg/kg
Result: No effects on fertility.

Effects on fetal development: Test Type: Embryo-fetal development
Species: Rat
Application Route: Intravenous injection
Developmental Toxicity: LOAEL: 10 µg/kg
Result: Malformations were observed. Reduced fetal weight.

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Intravenous injection
Developmental Toxicity: NOAEL: 3 µg/kg

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Intravenous injection
Developmental Toxicity: LOAEL: 0.03 µg/kg
Result: Malformations were observed.

Test Type: Embryo-fetal development
Species: Rabbit
Application Route: Intravenous injection
Developmental Toxicity: NOAEL: 0.01 µg/kg
SAFETY DATA SHEET

Tafluprost Formulation

Test Type: Embryo-fetal development
Species: Rat
Application Route: Intravenous injection
Developmental Toxicity: LOAEL: 1 µg/kg

Test Type: Embryo-fetal development
Species: Rat
Application Route: Intravenous injection
Developmental Toxicity: NOAEL: 0.3 µg/kg

Reproductive toxicity - Assessment: Clear evidence of adverse effects on development, based on animal experiments.

STOT-single exposure
Not classified based on available information.

Components:

Tafluprost:
Target Organs: Lungs, Cardio-vascular system
Assessment: Causes damage to organs.

STOT-repeated exposure
Not classified based on available information.

Components:

Tafluprost:
Target Organs: Lungs, Cardio-vascular system
Assessment: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Glycerine:
Species: Rat
NOAEL: 0.167 mg/l
LOAEL: 0.622 mg/l
Application Route: Inhalation (dust/mist/fume)
Exposure time: 13 Weeks

Species: Rat
NOAEL: 8,000 - 10,000 mg/kg
Application Route: Ingestion
Exposure time: 2 y

Species: Rabbit
NOAEL: 5,040 mg/kg
Application Route: Skin contact
Exposure time: 45 Weeks
Tafluprost Formulation

<table>
<thead>
<tr>
<th>Species</th>
<th>Rat</th>
</tr>
</thead>
<tbody>
<tr>
<td>LOAEL</td>
<td>0.01 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Intravenous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>6 Months</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Cardio-vascular system, Blood, Bone marrow, Kidney, Liver, spleen</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Dog</th>
</tr>
</thead>
<tbody>
<tr>
<td>NOAEL</td>
<td>0.0001 mg/kg</td>
</tr>
<tr>
<td>LOAEL</td>
<td>0.001 mg/kg</td>
</tr>
<tr>
<td>Application Route</td>
<td>Intravenous</td>
</tr>
<tr>
<td>Exposure time</td>
<td>39 Weeks</td>
</tr>
<tr>
<td>Target Organs</td>
<td>Cardio-vascular system, Eye</td>
</tr>
<tr>
<td>Symptoms</td>
<td>Dilatation of the pupil</td>
</tr>
</tbody>
</table>

**Aspiration toxicity**
Not classified based on available information.

**Experience with human exposure**

**Components:**

**Tafluprost:**
- Eye contact: Symptoms: dryness of the eyes, Blurred vision

**SECTION 12. ECOLOGICAL INFORMATION**

**Ecotoxicity**

**Components:**

**Glycerine:**
- Toxicity to fish: LC50 (Oncorhynchus mykiss (rainbow trout)): 54,000 mg/l
  Exposure time: 96 h
- Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 1,955 mg/l
  Exposure time: 48 h
- Toxicity to microorganisms: NOEC (Pseudomonas putida): > 10,000 mg/l
  Exposure time: 16 h
  Method: DIN 38 412 Part 8

**Persistence and degradability**

**Components:**

**Glycerine:**
- Biodegradability: Result: Readily biodegradable.
  Biodegradation: 92 %
  Exposure time: 30 d
  Method: OECD Test Guideline 301D
Bioaccumulative potential

Components:

Glycerine:
Partition coefficient: n-octanol/water : log Pow: -1.75

Tafluprost:
Partition coefficient: n-octanol/water : log Pow: 4.5

Mobility in soil
No data available

Other adverse effects
No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues : Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good

IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation

TDG
Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION

The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined
**SAFETY DATA SHEET**

**Tafluprost Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.10</td>
<td>04/09/2021</td>
<td>558015-00011</td>
<td>10/10/2020</td>
<td>03/15/2016</td>
</tr>
</tbody>
</table>

### SECTION 16. OTHER INFORMATION

**Full text of other abbreviations**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>CA AB OEL</td>
<td>Canada. Alberta, Occupational Health and Safety Code (table 2: OEL)</td>
</tr>
<tr>
<td>CA BC OEL</td>
<td>Canada. British Columbia OEL</td>
</tr>
<tr>
<td>CA QC OEL</td>
<td>Québec. Regulation respecting occupational health and safety, Schedule 1, Part 1: Permissible exposure values for airborne contaminants</td>
</tr>
<tr>
<td>CA AB OEL / TWA</td>
<td>8-hour Occupational exposure limit</td>
</tr>
<tr>
<td>CA BC OEL / TWA</td>
<td>8-hour time weighted average</td>
</tr>
<tr>
<td>CA QC OEL / TWAEV</td>
<td>Time-weighted average exposure value</td>
</tr>
</tbody>
</table>

**Sources of key data used to compile the Material Safety Data Sheet**

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.